At a glance
- Originator Pharmacia Corporation
- Class Antirheumatics
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 25 Mar 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 19 Dec 1996 Phase-I clinical trials for Rheumatic disorders in USA (Unknown route)
- 24 Jun 1996 Preclinical development for Rheumatic disorders in USA (Unknown route)